AstraZeneca collaborates with cancer research organisations to develop portfolio
This article was originally published in Scrip
Executive Summary
AstraZeneca has signed agreements with two research organisations, Cancer Research UK (CRUK) and the US-based Sarah Cannon Research Institute, that will allow the company to develop its experimental oncology products. Although the mechanisms of the interactions are different, both deals mean that AstraZeneca can advance its experimental compounds without drawing unnecessarily on its internal resources.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.